On the REPROCELL blog
Latest
From Biospecimen to Insight: How Human Tissue Improves Translational Confidence Bridging the Translational Gap in Drug Discovery
Explore how human tissue models enhance drug discovery by bridging the gap between preclinical findings and clinical success, improving translational confidence.
25 June 2026
Streamlining PBMC Processing for Reliable Results in Multi-Site Clinical Trials: Key Challenges and Solutions
Explore the challenges and solutions in PBMC processing for multi-site clinical trials, ensuring reliable results and data integrity for research success.
11 June 2026
AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy
REPROCELL's StemEdit platform enables the creation of hypoimmune iPSCs for scalable off-the-shelf cell therapies, reducing immune rejection and enhancing patient access.
04 June 2026
What Are Off-Target Effects in Cellular Gene Editing? Risks, Detection, and Solutions
Explore off-target effects in gene editing, from CRISPR risks and AI-driven detection to genomic safety in iPSC therapies.
20 May 2026
What to Look for in a Global Central Lab Partner for Clinical Trials
Selecting the right global central lab partner is crucial for clinical trial success, impacting data quality, logistics, and regulatory compliance.
14 May 2026
Corporate News
24 June 2026
02 June 2026
01 June 2026
Investor Relations News
- Jul 01, 2026
- Jun 24, 2026
- Jun 18, 2026


%20vial.jpg)








